This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Revenue rises 31% in Q2 but consolidated profit falls; new director appointed
CHEMBONDCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited results for the quarter and half-year ended 30 Sep 2026. Consolidated revenue rose 31.1% to Rs 9,576.93 lakh in Q2 and 31.7% to Rs 18,225.15 lakh in H1, but PAT fell 54.7% to Rs 326.02 lakh in Q2 and 4.8% to Rs 1,281.01 lakh in H1. Standalone H1 PAT rose 53.0% to Rs 606.02 lakh. Review was unqualified. Mamta Nirmal Shah, spouse of the CMD, joins the board; vote runs 1-30 Nov 2026.
Strong revenue growth but cost pressure cut consolidated profit; standalone profit rose. New director is the CMD's spouse, a governance watch point.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹95.77 Cr | ₹73.04 Cr | +31.1% |
| Operating profit | ₹6.91 Cr | ₹9.21 Cr | −24.9% |
| Profit after tax | ₹3.26 Cr | ₹7.19 Cr | −54.7% |
| EBITDA margin | 8.7% | 14.6% | −5.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.